Cartilage damage in the knee aﬀects millions of people worldwide with a continued rise in incidence. Currently, the only conventional solutions are symptoms (pain, stiﬀness) management, microfracture and in the end, replacing the joint with a prosthesis. Lately, cell therapies have emerged as a solution to regenerate cartilage e.g. tissue engineered autologous chondrocyte implantations (ACIs). However, ACIs often fail to integrate with the surrounding tissue, which results in failure rates up to 36%. Lamina’s new cell therapy from the Strasbourg University and Inserm aims to improve the cell approach by an innovative scaﬀold that houses Mesenchymal stem cells (MSCs) for optimal regeneration of the cartilage. By combining this patented scaﬀold together with growth factors and the MSCs, the product ensures fast recovery and high quality cartilage.
NLC formally founded and registered the new NLC Stepping Stone Fund
NLC – The European Healthtech Venture Builder formally founded and registered the new NLC Stepping Stone Fund. This means that the ‘marketing phase’ of…
How healthtech innovations arise during the COVID-19 crisis
At the start of the COVID-19 outbreak in Europe, NLC developed a website for people to share COVID-19 related ideas and innovations. With over…
NLC and MD squared conclude Framework Agreement for Venture Support
Amsterdam/Eindhoven NLC – the European HealthTech Venture Builder, has concluded a Framework Agreement with the Eindhoven based MD squared, a Medical Consultancy for Medical…